Vaxart Granted Extension by Nasdaq to Regain Compliance

Core Viewpoint - Vaxart, Inc. has received approval from the Nasdaq Hearings Panel to implement a plan to regain compliance with Nasdaq's minimum bid price requirement, contingent upon completing a reverse stock split and demonstrating compliance by specified deadlines [1][2][5]. Group 1: Compliance Plan - The company must obtain stockholder approval for a reverse stock split by September 5, 2025, complete the reverse stock split by October 6, 2025, and demonstrate compliance with Nasdaq Listing Rule 5550(a)(2) by October 17, 2025 [2][3]. - Vaxart's management presented a compliance plan during a hearing on August 14, 2025, which included changes to the reverse stock split proposal, such as narrowing the proposed ratio and reducing the number of authorized shares [3]. Group 2: Stakeholder Engagement - The company is actively engaging with stockholders to address their questions and concerns, including a virtual fireside chat held on August 20, 2025 [4]. - CEO Steven Lo emphasized the importance of stockholder support for the reverse stock split to secure the company's future on Nasdaq [5]. Group 3: Company Overview - Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using a proprietary delivery platform, which allows for storage and shipping without refrigeration [7]. - The company's vaccine development programs include candidates for coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV) [7].